By Paul Aisen, M.D. Director, Alzheimer’s Disease Cooperative Study Professor of Neurosciences, University of California San Diego There has been much discussion in the news lately as to whether the amyloid hypothesis is the correct path for research. The amyloid hypothesis is supported by a huge body of evidence, but to my thinking the most…
U.S. HHS released the National Plan to Address Alzheimer’s Disease: 2013 Update. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer’s disease by 2025 – and a review of progress over the past year.
The first-ever National Alzheimer’s Plan, initially released in May 2012, was mandated by the bipartisan National Alzheimer’s Project Act (P.L. 111-375), which Congress passed unanimously in 2010. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer’s disease by 2025 – and a review of progress over…
When a neuron gets blocked, the delicate harmony that allows the brain to operate seamlessly deteriorates. One result: diseases like Alzheimer’s. Understanding such blockages and how “traffic” should flow normally in healthy brain cells could offer hope to people with neurodegenerative diseases.
Toward that end, a research team led by University at Buffalo biologist Shermali Gunawardena, PhD, has shown that the protein presenilin plays an important role in controlling neuronal traffic on microtubule highways, a novel function that previously was unknown.
Additional data from the Phase III Gammaglobulin Alzheimer’s Partnership (GAP) study, including select analyses of subgroups, biomarker and imaging data, was presented at the Alzheimer’s Association International Conference (AAIC) in Boston, Massachusetts
On cognitive measures, an analysis of ApoE4 carrier patients who were treated with the 400mg/kg biweekly dose (n=87) of immunoglobulin (IG), found a statistically significant difference (p=0.012) in change from baseline in the 3MS score at 18 months versus placebo.
Paul Aisen, MD, Director of the ADCS, expands on the significance of the ADCS DAPC independent analysis of the semagacestat trial which was published last week in the New England Journal of Medicine.
A team of scientists, including Paul Aisen, MD, professor of neuroscience and director of the Alzheimer’s Disease Cooperative Study, issued a sort of post-mortem on semagacestat, a small-molecule gamma-secretase inhibitor that drug developer Eli Lilly hoped would prove to be an effective treatment for Alzheimer’s disease (AD).
Proposed preclinical stages for Alzheimer’s disease work well to predict who is most likely to progress to AD, according to a paper released online by Lancet Neurology.
Researchers led by Stephanie Vos and Pieter Jelle Visser at Maastricht University in the Netherlands and Anne Fagan and others at Washington University in St. Louis, Missouri, analyzed data from 311 cognitively normal elderly people seen at St. Louis’s Knight Alzheimer’s Disease Research Center.
We now have more accurate ways of diagnosing Alzheimer’s and are moving closer to developing drugs to directly attack the disease. Much of this work is still in the early stages, but experts are growing more hopeful about dealing with the debilitating disease, which currently has no cure.
NPR interviewed Dr. Reisa Sperling about the upcoming A4 trial and why it is unprecedented in the field of Alzheimer’s clinical research.
One of the longest and most anticipated Alzheimer drug studies in history is about to begin, and Dr. Reisa Sperling is wondering if people will come. It’s called the A4 study, and Sperling is the project leader.
In the largest-ever genetic analysis conducted on Alzheimer’s disease, an international group of researchers has identified 11 new genes associated with the disorder, doubling the number of known gene variants linked to it.
The International Genomic Alzheimer’s Project, a collaboration of two groups in the United States and two in Europe, scanned the DNA of 74,076 older volunteers from 15 countries — including people with and without the disease — to look for subtle gene variants involved in late-onset Alzheimer’s, the most common form.
Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.
A new online report from the National Institutes of Health (NIH) highlights recent progress in NIH-supported Alzheimer’s disease research.
The initiatives, objectives, and advances detailed in the 2012-2013 Alzheimer’s Disease Progress Report seek to help meet the Plan’s research goal—to effectively treat or prevent Alzheimer’s disease by 2025, if not sooner.
Incisive article from the NIA on challenges and new strategies for patient recruitment into AD clinical trials.
In this article we explore recruitment issues, including those unique to Alzheimer’s studies, and we suggest concrete steps such as establishing a structured consortium linking all of the registries of Alzheimer’s trials and establishing new partnerships with community and local organizations that can build trust and understanding among patients, caregivers, and providers.
A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer’s disease involving the so-called retromer protein complex.
Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer’s.
Exercise may help to keep the brain active in people with an increased risk of developing Alzheimer’s disease, according to a new study conducted by the Cleveland Clinic.
The findings suggest that even moderate amounts of physical activity may help to slow the progression of Alzheimer’s.
Mayo Clinic researchers have demonstrated in a mouse model that they can move small-molecule drugs through the blood-brain barrier.
Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications.
Dr. Neil Buckholtz of the NIA discusses ADNI in a summary of the recent presentations at the AAIC in Copenhagen and other Alzheimer’s research news.
From early morning to late evening, at symposium and plenary sessions, during poster sessions and coffee breaks, at add-on meetings and consortium sessions, some 4,300 investigators from 75 different countries shared recent findings and explored ways to overcome the challenges of finding ways to treat or prevent this complex disease.
Epidemiologic evidences support that habitual caffeine intake prevents memory decline during aging and reduces the risk to develop Alzheimer’s disease. So far, experimental studies addressed the impact of caffeine in models mimicking the amyloid pathology of AD. However, in vivo effects of caffeine in a model of AD-like tauopathy remain unknown.
A new study published in the British Medical Journal finds that anti-anxiety drugs may increase the risk of Alzheimer’s.
The drugs have been associated with short-term cognitive impairment, but the connection to Alzheimer’s has been less clear. Now, the new study finds a convincing, and apparently strong, link between benzodiazepines and Alzheimer’s disease.
A double-sided antibody targets enzyme to reduce levels of harmful amyloid-β protein in monkeys.
Identifying the genes involved in Alzheimer’s disease and related dementias is of course no easy task. From among the thousands of gene candidates in the human genome, we need to determine which are involved in onset and progression, and which increase risk or offer protection.